154 related articles for article (PubMed ID: 38045165)
1. A desktop review of evaluation of implementation of national medicines policies in SADC countries.
Modiba WK; Katerere DR; Mncwangi NP
Heliyon; 2023 Nov; 9(11):e22218. PubMed ID: 38045165
[TBL] [Abstract][Full Text] [Related]
2. National medicines policies - a review of the evolution and development processes.
Hoebert JM; van Dijk L; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
J Pharm Policy Pract; 2013; 6():5. PubMed ID: 24764540
[TBL] [Abstract][Full Text] [Related]
3. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list.
Naicker I; Suleman F; Perumal-Pillay VA
J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421
[TBL] [Abstract][Full Text] [Related]
4. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation.
Narsai K; Masekela FB; Leufkens HGM; Mantel-Teeuwisse AK
BMC Health Serv Res; 2024 Jan; 24(1):111. PubMed ID: 38245720
[TBL] [Abstract][Full Text] [Related]
5. Importation and distribution of unregistered medicines in the public sector: similarities, differences, and shared challenges among Southern African Development Community (SADC) countries.
Nyika A; Ngara B; Mutingwende I; Gwaza L
BMC Health Serv Res; 2022 Apr; 22(1):570. PubMed ID: 35484525
[TBL] [Abstract][Full Text] [Related]
6. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
[TBL] [Abstract][Full Text] [Related]
7. A rapid assessment of the National Regulatory Systems for medical products in the Southern African Development Community.
Dube-Mwedzi S; Kniazkov S; Nikiema JB; Kasilo OMJ; Fortin A; Tumusiime P; Mahlangu GN; Ndomondo-Sigonda M
J Pharm Policy Pract; 2020; 13():64. PubMed ID: 33029353
[TBL] [Abstract][Full Text] [Related]
8. Legislative landscape for traditional health practitioners in Southern African development community countries: a scoping review.
Abrams AL; Falkenberg T; Rautenbach C; Moshabela M; Shezi B; van Ellewee S; Street R
BMJ Open; 2020 Jan; 10(1):e029958. PubMed ID: 31915157
[TBL] [Abstract][Full Text] [Related]
9. Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.
't Hoen EFM; Kujinga T; Boulet P
J Pharm Policy Pract; 2018; 11():31. PubMed ID: 30524732
[TBL] [Abstract][Full Text] [Related]
10. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
[TBL] [Abstract][Full Text] [Related]
11. Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa.
Narsai K; Williams A; Mantel-Teeuwisse AK
South Med Rev; 2012 Jul; 5(1):31-7. PubMed ID: 23093897
[TBL] [Abstract][Full Text] [Related]
12. Health policy and integrated mental health care in the SADC region: strategic clarification using the Rainbow Model.
van Rensburg AJ; Fourie P
Int J Ment Health Syst; 2016; 10():49. PubMed ID: 27453722
[TBL] [Abstract][Full Text] [Related]
13. Regional trade and the nutrition transition: opportunities to strengthen NCD prevention policy in the Southern African Development Community.
Thow AM; Sanders D; Drury E; Puoane T; Chowdhury SN; Tsolekile L; Negin J
Glob Health Action; 2015; 8():28338. PubMed ID: 26205364
[TBL] [Abstract][Full Text] [Related]
14. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
[TBL] [Abstract][Full Text] [Related]
15. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Global Health; 2017 Aug; 13(1):53. PubMed ID: 28764738
[TBL] [Abstract][Full Text] [Related]
16. How and why pharmaceutical reforms contribute to universal health coverage through improving equitable access to medicines: a case of Ghana.
Koduah A
Front Public Health; 2023; 11():1163342. PubMed ID: 37483923
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
[TBL] [Abstract][Full Text] [Related]
18. Where National Medicines Policies Have Taken Us With Patient Involvement and Health Technology Assessment in Africa.
Sehmi K; Wale JL
Front Med Technol; 2022; 4():810456. PubMed ID: 35281672
[TBL] [Abstract][Full Text] [Related]
19. Value added medicines: what value repurposed medicines might bring to society?
Toumi M; Rémuzat C
J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
